<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757922</url>
  </required_header>
  <id_info>
    <org_study_id>2020-6885</org_study_id>
    <nct_id>NCT04757922</nct_id>
  </id_info>
  <brief_title>Stop Ovarian Cancer Young; Effect of the Opportunistic Salpingectomy on Age of Menopause</brief_title>
  <acronym>STOPOVCAyoung</acronym>
  <official_title>Stop Ovarian Cancer Young; Effect of the Opportunistic Salpingectomy on Age of Menopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the long-term safety of on the onset of menopause.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the long-term safety of on the onset of menopause. To&#xD;
      investigate the effect of Opportunistic Salpingectomy on the age of menopause, we will&#xD;
      compare age of menopause in women who underwent sterilization through opportunistic&#xD;
      salpingectomy with a control group consisting of women who underwent sterilization by tubal&#xD;
      ligation or who had no sterilization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2036</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2035</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>Menopausal age</measure>
    <time_frame>At end of follow-up (follow up ends at age of menopause with a maximum follow-up time of 15 years)</time_frame>
    <description>The age of reaching natural menopause (e.g. last menstruation &gt; 1 year ago )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decision regret</measure>
    <time_frame>1 year post surgery and at age of menopause</time_frame>
    <description>The decision regret regarding their choice of sterilization method.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Salpingectomy</condition>
  <condition>Tubal Ligation</condition>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Intervention: bilateral salpingectomy</arm_group_label>
    <description>Premenopausal women between 35 and 45 years of age, who will undergo sterilization through Opportunistic Salpingectomy will be asked to participate in the STOPOVCAyoung study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: tubal ligation or no sterilization</arm_group_label>
    <description>The control group will consists of women who chose for sterilization by clips/tubal ligation supplemented by friend/acquaintances, around the same age, who are not planning to undergo sterilization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Opportunistic salpingectomy / bilateral salpingectomy</intervention_name>
    <description>An opportunistic salpingectomy refers to removal of the salpinges without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases. Therefore, a so-called opportunistic salpingectomy is a method of female sterilization.</description>
    <arm_group_label>Intervention: bilateral salpingectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women who underwent sterilization (bilateral salpingectomy / tubal ligation) supplemented&#xD;
        by friend/acquaintances, around the same age, who are not planning to undergo&#xD;
        sterilization.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Intervention group&#xD;
&#xD;
          -  Undergoing an Opportunistic Salpingectomy as sterilization method&#xD;
&#xD;
          -  Premenopausal status at enrolment&#xD;
&#xD;
          -  Age between 35 and 45 years&#xD;
&#xD;
          -  Will have residual ovarian tissue after surgery&#xD;
&#xD;
          -  Able to understand the written or spoken Dutch language&#xD;
&#xD;
          -  Gives consent for participating in surveys&#xD;
&#xD;
        Control group&#xD;
&#xD;
          -  Premenopausal status at enrolment&#xD;
&#xD;
          -  Either sterilization by tubal ligation or no sterilization at all&#xD;
&#xD;
          -  Age between 35 and 45 years&#xD;
&#xD;
          -  Able to understand the written or spoken Dutch language&#xD;
&#xD;
          -  Gives consent for participating in surveys&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal status at enrolment&#xD;
&#xD;
          -  Under the age of 35 or above 45&#xD;
&#xD;
          -  Previous salpingectomy of oophorectomy&#xD;
&#xD;
          -  Previous hysterectomy&#xD;
&#xD;
          -  Women with abnormal karyotype (such as Turner Syndrome and Fragile X syndrome)&#xD;
&#xD;
          -  Underwent chemotherapy or radiation&#xD;
&#xD;
          -  Unable to understand the written or spoken Dutch language&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jurgen MJ Piek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina ziekenhuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanne A de Hullu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Nijmegen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jurgen MJ Piek, MD, PhD</last_name>
    <phone>+31644474099</phone>
    <email>jurgen.piek@catharinaziekenhuis.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Malou E Gelderblom, MD</last_name>
    <phone>+31612615984</phone>
    <email>malou.gelderblom@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Jurgen MJ Piek, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001 Nov;195(4):451-6.</citation>
    <PMID>11745677</PMID>
  </reference>
  <reference>
    <citation>Reade CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. J Obstet Gynaecol Can. 2014 Feb;36(2):133-140. doi: 10.1016/S1701-2163(15)30659-9. Review.</citation>
    <PMID>24518912</PMID>
  </reference>
  <reference>
    <citation>Falconer H, Yin L, Gr√∂nberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2015 Jan 27;107(2). pii: dju410. doi: 10.1093/jnci/dju410. Print 2015 Feb.</citation>
    <PMID>25628372</PMID>
  </reference>
  <reference>
    <citation>van Lieshout LAM, Steenbeek MP, De Hullu JA, Vos MC, Houterman S, Wilkinson J, Piek JM. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. Cochrane Database Syst Rev. 2019 Aug 28;8:CD012858. doi: 10.1002/14651858.CD012858.pub2.</citation>
    <PMID>31456223</PMID>
  </reference>
  <reference>
    <citation>Hanley GE, Kwon JS, Finlayson SJ, Huntsman DG, Miller D, McAlpine JN. Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada. Am J Obstet Gynecol. 2018 Aug;219(2):172.e1-172.e8. doi: 10.1016/j.ajog.2018.05.019. Epub 2018 May 28.</citation>
    <PMID>29852159</PMID>
  </reference>
  <reference>
    <citation>McAlpine JN, Tone AA, Hanley GE. Opportunistic Salpingectomy: We Chose to Act, Not Wait. J Obstet Gynaecol Can. 2016 May;38(5):425-7. doi: 10.1016/j.jogc.2016.04.084. Epub 2016 May 6.</citation>
    <PMID>27261215</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Salpingectomy</keyword>
  <keyword>Sterilization</keyword>
  <keyword>Tubal ligation</keyword>
  <keyword>Opportunistic salpingectomy</keyword>
  <keyword>Menopausal age</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

